article thumbnail

2024 IDstewardship Year End Review

IDStewardship

It is likely our newsletter will remain a key communication for reaching the IDstewardship community.Not knowing what 2025 will hold, it is likely unpredictable events in our future will further guide what activities we engage in this year. Steven Smoke, Pharm.D., It is likely there will be greater activity on Bluesky and less activity on X.

article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

In 2012, Dame June was elected as the first chair of the European Pharmacovigilance Risk Assessment Committee, MHRA added. MHRA also noted that Dame June’s key interests are in monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Healthware appoints Paolo Guglielmoni as head of experience

pharmaphorum

Digital health consulting, marketing communications group Healthware has appointed Paolo Guglielmoni as its new head of experience. He brings 22 years of professional copywriting and advertising experience to the role, gained during his time with Leo Burnett up until 2012, and from his entrepreneurial and consulting activities since then.

article thumbnail

A history of Johnson & Johnson

pharmaphorum

In 2012, J&J agreed to pay US $181 million to 26 states in order to settle these claims – though another lawsuit related to the drug (for $8 billion, eventually reduced to $6.8 CEO Alex Gorsky, who was appointed in 2012. Risperdal is well-known due to the controversy in the US following its product launch in 1994.

Vaccines 126
article thumbnail

International regulation: the importance of quality assurance in drug development

European Pharmaceutical Review

Since the first ADC was approved by the EMA in 2012, they have generated a great deal of interest in the oncology field because of their potential to address many of the challenges of traditional chemotherapy options. Teams must also accept the variety of analytical procedures these regulatory agencies prefer.

article thumbnail

What can pharma marketing learn from other regulated industries?

pharmaphorum

“A lot of printed materials have been migrated to digital so that patients can opt-in to receive digital communications or HCPs can receive digital product or disease state information in the form of rep-triggered emails and microsites. Joanna Carlish. The idea is about really tapping into where the customer is in their journey.

article thumbnail

Enabling the leaders of the future

pharmaphorum

From clear communication with an unsettled, dispersed workforce to maintaining positive energy and managing people’s working hours, the need for open, inclusive and empathetic leadership has never been more important. . COVID-19 has amplified what is expected of leaders in workplaces around the world.